Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001807437
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name Phone

E-Mail Address

Address of Issuer

144: Issuer Information

Name of Issuer UNITY BIOTECHNOLOGY, INC.

SEC File Number 001-38470

285 East Grand Ave. South San Francisco CALIFORNIA

94080

Phone (650)-416-1192

Name of Person for Whose Account the Securities are To Be Sold Ghosh Anirvan

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer
Relationship to Issuer Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	E*TRADE Securities LLC Harborside 2, 200 Hudson Street Ste. 501 Jersey City NJ 07311	1246	3078.70	82222	09/14/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	this	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock (09/13/2023	Restricted Stock Units granted in 2022 under the Issuer's 2018 Incentive Award Plan	UNITY Biotechnology, Inc.			1246	09/13/2023 N/A	A

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Anirvan Ghosh c/o UNITY Biotechnology, Inc. 285 East Grand Ave. South San Francisco CA 94080	Restricted Stock Units granted in 2020 under the Issuer's 2018 Incentive Award Plan	06/14/2023	1212	4108.68
Anirvan Ghosh c/o UNITY Biotechnology, Inc. 285 East Grand Ave. South San Francisco CA 94080	Restricted Stock Units granted in 2021 under the Issuer's 2018 Incentive Award Plan	06/26/2023	1177	3766.64
Anirvan Ghosh c/o UNITY Biotechnology, Inc. 285 East Grand Ave. South San Francisco CA 94080	Restricted Stock Units granted in 2021 under the Issuer's 2018 Incentive Award Plan	07/31/2023	1020	2917.02
Anirvan Ghosh c/o UNITY Biotechnology, Inc. 285 East Grand Ave. South San Francisco CA 94080	Restricted Stock Units granted in 2022 under the Issuer's 2018 Incentive Award Plan	08/02/2023	581	1708.09

144: Remarks and Signature

Remarks 1. Share number reflects post-split units after 1-for-10 reverse stock split as of 10/19/22.

Date of Notice 09/15/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Alexander Nguyen as attorney-in-fact for Anirvan Ghosh pursuant to Power of Attorney

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)